Cargando…

Clinical significance of immunohistochemistry to detect BRAF V600E mutant protein in thyroid tissues

This study investigated the feasibility of using immunohistochemistry (IHC) instead of PCR to detect BRAF V600E mutant protein in papillary thyroid carcinoma (PTC), and to determine the value of using preoperative BRAF V600E mutant protein by IHC to assist in the diagnosis of thyroid nodule patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yini, Liu, Lidan, Liu, Ye, Cao, Nan, Wang, Lifen, Xing, Chengjuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078443/ https://www.ncbi.nlm.nih.gov/pubmed/33879712 http://dx.doi.org/10.1097/MD.0000000000025566

Ejemplares similares

The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy
por: Hannan, Enda J., et al.
Publicado: (2017)

BRAF V600E mutation and the Bethesda System for Reporting Thyroid Cytopathology of fine-needle aspiration biopsy for distinguishing benign from malignant thyroid nodules
por: Sheng, Danli, et al.
Publicado: (2021)

Cutaneous metastasis of ascending colon cancer harboring a BRAF V600E mutation: A rare case report
por: Liao, Lianggong, et al.
Publicado: (2020)

Validation of Immunohistochemistry for the Detection of BRAF V600E-Mutated Lung Adenocarcinomas
por: Gow, Chien-Hung, et al.
Publicado: (2019)

BRAF V600E mutation as a novel mechanism of acquired resistance to ALK inhibition in ALK-rearranged lung adenocarcinoma: A case report
por: Sui, Aixia, et al.
Publicado: (2021)

The expression and prognostic significance of Drp1 in lung cancer: A bioinformatics analysis and immunohistochemistry
por: Yu, Lingling, et al.
Publicado: (2019)

Comparison of Immunohistochemistry and Direct Sanger Sequencing for Detection of the BRAF(V600E) Mutation in Thyroid Neoplasm
por: Oh, Hye-Seon, et al.
Publicado: (2018)

Immunohistochemistry cannot replace DNA analysis for evaluation of BRAF V600E mutations in papillary thyroid carcinoma
por: Szymonek, Monika, et al.
Publicado: (2017)

VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting BRAF(V600E) Mutation in Papillary Thyroid Cancer
por: Choden, Sonam, et al.
Publicado: (2020)

VE1 immunohistochemistry is an adjunct tool for detection of BRAF (V600E) mutation: Validation in thyroid cancer patients
por: Rashid, Faiza A., et al.
Publicado: (2020)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

The Combined Utility of HBME-1 and Galectin-3 Immunohistochemistry and BRAF V600E Mutations in the Diagnosis of Papillary Thyroid Carcinoma
por: Ramkumar, Subramaniam, et al.
Publicado: (2021)

Clinical Significance of PEAK1 Expression and BRAF V600E Mutation in Papillary Thyroid Cancer
por: Li, P., et al.
Publicado: (2022)

Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma
por: Ida, Cristiane M, et al.
Publicado: (2013)

BRAF‐V600E immunohistochemistry in a large series of glial and glial–neuronal tumors
por: Breton, Quentin, et al.
Publicado: (2017)

BRAF V600E Immunohistochemistry Predicts Prognosis of Patients with Cutaneous Melanoma in Thai population
por: Meevassana, Jiraroch, et al.
Publicado: (2022)

Utility of BRAF VE1 Immunohistochemistry as a Screening Tool for Colorectal Cancer Harboring BRAF V600E Mutation
por: Kwon, Jeong-Hwa, et al.
Publicado: (2018)

Reliability of BRAF mutation detection using plasma sample: A systematic review and meta-analysis
por: Ye, Peng, et al.
Publicado: (2021)

Expression of HIF-1α/PKM2 axis correlates to biological and clinical significance in papillary thyroid carcinoma
por: Hao, Zengfang, et al.
Publicado: (2023)

A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer
por: Cui, Guanghui, et al.
Publicado: (2017)

Concordance of RT-qPCR with immunohistochemistry and its beneficial role in breast cancer subtyping
por: Li, Yilun, et al.
Publicado: (2023)

Reflectance confocal microscopy features of BRAF V600E mutated thin melanomas detected by immunohistochemistry
por: Urvanegia, Ana Claudia, et al.
Publicado: (2017)

Selective inhibition of V600E-mutant BRAF gene induces apoptosis in thyroid carcinoma cell lines
por: Park, Kyoung Sik, et al.
Publicado: (2021)

KRAS, NRAS, BRAF signatures, and MMR status in colorectal cancer patients in North China
por: Lian, Shen-Yi, et al.
Publicado: (2023)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
por: Peker, Yasar Subutay, et al.
Publicado: (2018)

VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer
por: Schafroth, Christian, et al.
Publicado: (2015)

Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
por: Schirosi, Laura, et al.
Publicado: (2016)

Immunohistochemistry as an accurate tool for the assessment of BRAF V600E and TP53 mutations in primary and metastatic melanoma
por: Rusu, Stefan, et al.
Publicado: (2021)

KIF23 is a potential biomarker of diffuse large B cell lymphoma: Analysis based on bioinformatics and immunohistochemistry
por: Gong, Yuqi, et al.
Publicado: (2022)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
por: Xu, Ting, et al.
Publicado: (2022)

An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer
por: Xue, Yaohua, et al.
Publicado: (2017)

Prognostic Significance of BRAF V600E Mutation and CPSF2 Protein Expression in Papillary Thyroid Cancer
por: Ivković, Irena, et al.
Publicado: (2022)

Coexistence of Papillary Thyroid Carcinoma With Thyroid MALT Lymphoma in a Patient With Hashimoto's Thyroiditis: A Clinical Case Report
por: Shen, Guohua, et al.
Publicado: (2015)

MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers
por: Choi, Yong Won, et al.
Publicado: (2016)

Upregulation and the clinical significance of KCNQ1OT1 and HAGLROS lncRNAs in papillary thyroid cancer: An observational study
por: Mutlu Icduygu, Fadime, et al.
Publicado: (2023)

Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer
por: Zhang, Zongjing, et al.
Publicado: (2014)

Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer
por: Liu, Rengyun, et al.
Publicado: (2018)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

Induction of Resistance to BRAF Inhibitor Is Associated with the Inability of Spry2 to Inhibit BRAF-V600E Activity in BRAF Mutant Cells
por: Ahn, Jun-Ho, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_l5c2dhg583n3np5qhjs9fl1tgk